
The generic drug Sofosbuvir for treating chronic Hepatitis C in India is soon to be launched under the brand name 'Hepcvir'.
"Sofusbuvir marks a new era of medicines in oral treatment of Hepatitis C which reduce the need for injectables," Cipla Chief Medical Officer Jaideep Gogtay said.
Advertisement
Cipla has signed a licensing agreement with Gilead to manufacture the drug Sofosbuvir and it will be made available to Indian patients in a week's time.
"Cipla has always brought accessible and affordable medicines to fight against diseases like AIDS and Hepatitis B; hence, Cipla has made it a priority to bring Hepcvir to patients in India as well as the other developing nations," Cipla MD & Global CEO Subhanu Saxena said.
Dr Reddy's entered into an agreement with Hetero to distribute and market generic version of US-firm Gilead Sciences' Hepatitis C drug under the brand 'Resof' in India.
Source: Medindia
Dr Reddy's entered into an agreement with Hetero to distribute and market generic version of US-firm Gilead Sciences' Hepatitis C drug under the brand 'Resof' in India.
Source: Medindia
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News

The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.

The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.

Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.

Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.

In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.